Abstract: The article comments on a recent ruling of the Czech Constitutional
Court in the context of the public health insurance system and the way the
rules of payments from this system towards various medicines are being set by
the relevant ministry. The article explains the way the system has worked and
it comments on the question of conformity of the national legislation with that
of the EC. It also introduces the political and diplomatic circumstances that
had occurred before this ruling. By doing so, the article provides its readers
not only with a legal analysis of the system (which is the main purpose of this
text), but also an insight into the most obvious circumstance that must have
had impact on the exact content of the courts decision.
Keywords: Czech pharmaceutical law, public health insurance, pricing of pharmaceuticals, EC – national law relationship, constitutional court, conformity with EC legislation, transparency directive, constitutional right, fair process